Jane de Lartigue, PhD

Articles

5 PARP-Related Questions for Melinda L. Telli, MD

August 2nd 2012

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.

The PARP Inhibitors: Down But Not Out

July 31st 2012

In spite of the setbacks, researchers remain hopeful that a better understanding of the mechanism of action for PARP inhibitors will lead to effective treatment of a wide variety of cancers.

Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells

July 5th 2012

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.

Five Questions for Leonard M. Neckers, PhD

April 24th 2012

Leonard M. Neckers, PhD, has been studying the role of the molecular chaperone Hsp90 in signal transduction and the translational development of Hsp90-targeted anticancer agents for two decades.

Targeting Hsp90: Researchers Aim to Thwart Chaperones of the 'Guardian of the Proteome'

April 24th 2012

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

MET Receptor Pathway: A Bounty of Targeted Options Explored

March 23rd 2012

The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.

Five Questions for Jill M. Siegfried, PhD

March 22nd 2012

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

Targeting HER2: Pertuzumab Puts the Spotlight on Dual Blockade Strategies

March 2nd 2012

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

2 Leading Breast Cancer Researchers Discuss Emerging Anti-HER2 Therapeutics

March 1st 2012

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

What Turns a Good Cell Bad? Exploiting the Hallmarks of Cancerous Cells

February 2nd 2012

Hanahan and Weinberg initially outlined 6 hallmarks that they believed were essential to the transformation of normal cells into malignant cancer cells in most, if not all, human cancers.

5 Questions for Yuri Lazebnik, PhD

February 2nd 2012

Dr. Yuri Lazebnik's research focuses on how cells become cancerous, how cancer cells evolve, and how they can be killed selectively.

Targeted Cancer Therapies: Awakening the

December 22nd 2011

As its moniker As its moniker "guardian of the genome" suggests, p53 has become recognized as one of the most important cancer-related molecules in the cell.

Phosphorylation: The Master Switch of the Cell

December 15th 2011

Since its discovery, phosphorylation has come to be recognized as a global regulator of cellular activity, and abnormal phosphorylation is implicated in a host of human diseases.

5 Questions for Martin Steffen, MD, PhD

December 15th 2011

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Targeting PI3K/Akt Pathway: 20 Years of Progress

November 21st 2011

This year marks more than 20 years of research into the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.

5 Questions for Josep Tabernero, MD

November 17th 2011

Josep Tabernero, MD, is actively involved in clinical research with molecular targeted therapies, with a focus on EGFR-family and PI3K-Akt-mTOR pathway inhibitors, in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.

Oncogenic Signaling of the EGFR: Familiar Target Faces New Questions

October 3rd 2011

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

The SCF/KIT Pathway's Roles: Interest in Therapeutic Targets Is Growing

September 2nd 2011

The breadth of the stem cell factor (SCF)/ KIT signaling pathway oncogenic functions and potential role as a therapeutic target are just now becoming clear.

JAK-STAT Signaling Has Many Faces: Inhibitors Offer Hope in Rare Blood Cancers

July 27th 2011

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.